SAN DIEGO, April 1, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that effective as of the close of the market on Monday, March 31, 2014, the Company was added to the Russell 2000® and the Russell 3000® indexes, as part of the quarterly Initial Public Offering (IPO) update to the Russell indexes.
Help employers find you! Check out all the jobs and post your resume.
